Martha-Maria Krankenhaus Halle-Doelau gGmbH — Clinical Trial Site

43 Registered trials

15 Currently recruiting

Organisation

Martha-Maria Krankenhaus Halle-Doelau gGmbH

Location

Halle (saale), Germany

Identifier

ORG-100044035

Address

Roentgenstrasse 1, Doelau, 06120, Germany

Departments

4505 :Klinik für Innere Medizin II
7110:Klinik fuer Neurologie
Clinic for internal medicine II
Department for Internal Medicine II
department of clinic for internal medicine ll
Department of Neurology
Innere Medizin II
Innere Medizin II - Pneumologie
Klinik fuer Innere Medizin II
Klinik für Innere Medizin II
Klinik für Innere Medizin II Studiensekretariat
Klinik für Innere Medizin II - Pneumologie
Klinik für Innere Medizin II-Pneumologie
Klinik für Neurologie
Klinik für Urologie
Klinik für Urologie, Kinderurologie und Urologische Onkologie
N/A
NA
Oncology
Pneumologie
Studienambulanz Innere Medzin III
Studiensekretariat MVZ
Studiensekretariat, MVZ, E0

Clinical trials at this site (43)

Search interface

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or… Pending

2025-523461-17-01 LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANC 5
A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Pending

2025-523576-23-00 Unresectable Stage III non-small cell lung cancer witho 5
The AIRTIVITY TM Study: A study to find out whether BI 1291583 helps people with bronchiectasis Recruiting

2024-518589-29-00 Bronchiectasis 5 2025-08-21
A Study to Learn About the Study Medicine Called Sigvotatug Vedotin in People with Locally Advanced, Unresectable, or Metastatic Non-Small C… Recruiting

2024-517968-36-00 non-small cell lung cancer 5 2025-07-08
A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced … Recruiting

2023-503221-19-00 Advanced Non-Small Cell Lung Cancer 4 2024-04-18
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi… Recruiting

2025-521546-23-00 Secondary progressive multiple sclerosis 5 2026-04-21
Thrombolysis with Tenecteplase for Acute Ischemic Stroke in Patients taking Direct Oral Anticoagulants Recruiting

2025-521762-99-00 acute ischemic stroke 5 2026-03-09
Safety and efficacy of BNT327, an investigational therapy, in combination with chemotherapy for patients with untreated small-cell lung canc… Recruiting

2024-515765-34-00 English First-line extensive-stage small-cell lung canc 5 2026-02-04
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin i… Recruiting

2024-518365-10-00 Previously Untreated Advanced or Metastatic Non-Squamou 5 2025-10-28
A Study of Navlimetostat (BMS986504) in Participants with Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer with Homozygous MTAP… Recruiting

2024-519814-29-00 Advanced or Metastatic Non-small Cell Lung Cancer 4 2025-09-12
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Smal… Recruiting

2024-512302-25-00 Resected or Unresectable KRAS G12C-mutant Non-Small Cel 5 2025-06-06
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Can… Recruiting

2023-509340-10-00 Patients with HLA-A2 positive phenotype and metastatic 5 2024-10-29
Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting

2023-508012-35-00 Newly diagnosed NSCLC with resectable clinical Stage II 5 2024-10-02
A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe… Recruiting

2023-503412-33-00 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small 5 2024-03-29
A Study Evaluating the Overall Survival of Patients with Extensive Stage Small Cell Lung Cancer Receiving Trilaciclib or Placebo prior to To… Recruiting

2022-502357-34-00 Extensive Stage Small Cell Lung Cancer 5 2023-09-27
Efficacy and Safety Study of Nipocalimab for Adults with CIDP Recruiting

2023-508425-28-00 Chronic Inflammatory Demyelinating Polyneuropathy 4 2022-10-24
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Patients With Stage III Unresectabl… Recruiting

2023-506891-28-00 The target population of interest in this study is part 5 2022-05-02
Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended

2024-513621-23-00 Advanced/metastatic non-small cell lung cancer (NSCLC) 5 2025-04-18
BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) with Chemotherapy vs Atezolizumab with Chemotherapy as First-line Therapy in Part… Ended

2024-515740-23-00 Extensive-Stage Small Cell Lung Cancer (ES-SCLC) 5 2025-03-25
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Ended

2024-512998-27-00 Non-Small Cell Lung Cancer 5 2025-02-21
A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended

2023-504753-12-00 Lung Cancer, Non-Small Cell 5 2024-10-01
A study of sigvotatug vedotin versus docetaxel in previously treated non-small cell lung cancer (Be6A Lung-01) Ended

2023-503827-25-01 Non-Small Cell Lung Cancer (NSCLC) 5 2024-02-16
Study which tests 2 medications (SB27, Keytruda) to compare how effective, safe and well tolerated in a large number of metastatic non-squam… Ended

2023-507448-36-00 Non-small Cell Lung Cancer 5 2024-02-16
Phase 3 study of belzutifan plus pembrolizumab as adjuvant treatment in renal cell carcinoma (RCC) Ended

2023-505023-31-00 Renal cell carcinoma 5 2023-11-17